会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明授权
    • Reconfigurable power distribution panel
    • 可配置配电盘
    • US07256984B2
    • 2007-08-14
    • US11125666
    • 2005-05-10
    • Minchul KimKeith GibsonKeith Leicht
    • Minchul KimKeith GibsonKeith Leicht
    • H02B1/26H02B1/04H02B1/20
    • H05K7/1457
    • The present invention provides a reconfigurable power distribution panel, a power distribution system, a method for reconfiguring a power distribution panel, and a method for manufacturing a reconfigurable power distribution panel. The reconfigurable distribution panel, among other elements, may include a first bus bar having a first plurality of contact points thereon and a plurality of circuit protection locations associated therewith and a second bus bar located proximate the first bus bar and having a second plurality of contact points thereon, the second plurality of contact points having the same plurality of circuit protection locations associated therewith. The reconfigurable power distribution panel may further include first and second coupling devices coupleable to a one of the first or second bus bars, respectively, at a chosen circuit protection location, and a circuit protection device coupleable to either the first bus bar or the second bus bar at the chosen circuit protection location by the selection of either the first or second coupling devices.
    • 本发明提供了一种可重新配置的配电盘,配电系统,配电面板的重新配置方法及可重构配电面板的制造方法。 除了其他元件之外,可重新配置的配电盘可以包括其上具有第一多个接触点的第一汇流条和与其相关联的多个电路保护位置以及位于第一汇流条附近并具有第二多个触点的第二汇流条 点上,第二多个接触点具有与之相关联的多个电路保护位置。 可重构配电面板还可以包括分别在所选择的电路保护位置处可耦合到第一或第二汇流条中的一个的第一和第二耦合装置,以及可耦合到第一汇流条或第二总线 通过选择第一或第二耦合装置在所选择的电路保护位置处的条。
    • 10. 发明申请
    • Substituted quinolines as antitumor agents
    • US20070021407A1
    • 2007-01-25
    • US11374423
    • 2006-03-14
    • Francis BoyleKeith GibsonKevin Foote
    • Francis BoyleKeith GibsonKevin Foote
    • A61K31/496A61K31/4709A61K31/4704C07D403/02
    • C07D215/56C07D215/54C07D231/12C07D233/56C07D249/08C07D401/12C07D405/12C07D409/12C07D413/12C07D417/12
    • The invention provides a compound of Formula (Ia), or a pharmaceutically acceptable salt, pro-drug or solvate thereof. wherein: n is 0 or 1; Y is selected from —NH—, —O—, —S—, or —NR7— where R7 is alkyl of 1-6 carbon atoms; R5 is cyano, fluoro, chloro or bromo; R6 is cycloalkyl of 3 to 7 carbon atoms, which may be optionally substituted with one or more alkyl of 1 to 6 carbon atom groups; or is a pyridinyl, pyrimidinyl, or phenyl ring; wherein the pyridinyl, pyrimidinyl, or phenyl ring may be optionally mono- di-, or tri-substituted; or R6 is a group —R8—X—R9 where R8 is a divalent cycloalkyl of 3 to 7 carbon atoms, which may be optionally further substituted with one or more alkyl of 1 to 6 carbon atom groups; or is a divalent pyridinyl, pyimidinyl, or phenyl ring; wherein the pyridinyl, pyrimidinyl, or phenyl ring may be optionally further substituted with one or more groups; and where X is selected from —NH—, —O—, —S—, CH2 or —NR7′— where R7′ is alkyl of 1-6 carbon atoms, and R9 is a group (CH2)mR10 where m is 0, or an integer of from 1-3 and R10 is an optionally substituted aryl or optionally substituted cycloalkyl ring of up to 10 carbon atoms, or R10 is a optionally substituted heterocyclic ring or an N-oxide of any nitrogen containing ring; R1, R2, R4 are independently selected from hydrogen, hydroxy, halogeno, cyano, nitro, trifluoromethyl, C1-3alkyl, —NR11R12— (wherein R11 and R12, which may be the same or different each represents hydrogen, or C1-3alkyl), or a group R13—X1—(CH2)x wherein x is 0 or an integer of from 1 to 3, X1 represents a direct bond, —O—, —CH2—, —OC(O)—, —C(O)—, —S—, —SO—, —SO2—, —NR14C(O)—, —NR14C(O)O—, —C(O)NR15—, —C(O)ONR15—, —SO2NR16—, —NR17SO2— —NR18— or —NR18NR18— (wherein R14, R15, R16, R17 and R18 each independently represents hydrogen, C1-3alkyl or C1-3alkoxyC2-3alkyl)), and R13 is hydrogen, optionally substituted hydrocarbyl, or optionally substituted heterocyclyl; and R3 is selected from (i) a group of formula —X1—Rx—(OH)p where X1 is as defined above, Rx is an alkylene, alkenylene or alkynylene chain, optionally interposed with a heteroatom or a heteocyclic ring and p is 1 or 2; (ii) a group of formula R13a—(CH2)y—X1—(CH2)x where R13 a is as defined for R13 above, and X1 and x are as defined above, y is 0 or an integer between 1 and 5, wherein (CH2)y is optionally interposed by an X1 group; (iii) a group of formula —X1—Ry—NRz—Ry′—S—Ry″ where X1 is as defined above, Ry, Ry′ and Ry″ are independently selected from alkyl, alkenyl or alkynyl chains, and Rz is hydrogen or alkyl, or Rz and Ry″ are joined together to form an optionally substituted nitrogen and sulphur containing ring; (iv) a group of formula —X1—Rx′—(C3-6cycloalkyl) where X1 is as defined above and Rx′ is an alkylene, alkenylene or alkynylene chain, optionally interposed with a heteroatom a group of the formula —X1—C1-5alkyl where X1 is as defined above and C1-5alkyl is substituted by one more substituents independently selected from chloro and cyano; (v) a group of the formula —X1—C1-3alkyl-CO—NR18NR18—R20 where R18 is as defined above and R20 is selected from hydrogen or C1-5alkoxycarbonyl; or (vi) a heterocyclic ring. The invention also provides a process for the preparation of a compound of Formula (Ia), pharmaceutical compositions of a compound of Formula (Ia) and methods for the treatment or prevention of cancer comprising administering an effective amount of a compound of Formula (1a).